Cardiac glycosides with target at direct and indirect interactions with nuclear receptors

Biomed Pharmacother. 2020 Jul:127:110106. doi: 10.1016/j.biopha.2020.110106. Epub 2020 Apr 2.

Abstract

Cardiac glycosides are compounds isolated from plants and animals and have been known since ancient times. These compounds inhibit the activity of the sodium potassium pump in eukaryotic cells. Cardiac glycosides were used as drugs in heart ailments to increase myocardial contraction force and, at the same time, to lower frequency of this contraction. An increasing number of studies have indicated that the biological effects of these compounds are not limited to inhibition of sodium-potassium pump activity. Furthermore, an increasing number of data have shown that they are synthesized in tissues of mammals, where they may act as a new class of steroid hormones or other hormones by mimicry to modulate various signaling pathways and influence whole organisms. Thus, we discuss the interactions of cardiac glycosides with the nuclear receptor superfamily of transcription factors activated by low-weight molecular ligands (including hormones) that regulate many functions of cells and organisms. Cardiac glycosides of endogenous and exogenous origin by interacting with nuclear receptors can affect the processes regulated by these transcription factors, including hormonal management, immune system, body defense, and carcinogenesis. They can also be treated as initial structures for combinatorial chemistry to produce new compounds (including drugs) with the desired properties.

Keywords: Cardiac glycoside; Digoxin; Nuclear receptor; Ouabain.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiac Glycosides / pharmacology*
  • Humans
  • Receptors, Cytoplasmic and Nuclear / drug effects*
  • Receptors, Cytoplasmic and Nuclear / physiology*

Substances

  • Cardiac Glycosides
  • Receptors, Cytoplasmic and Nuclear